This is an old revision of this page, as edited by Hcheney (talk | contribs) at 16:30, 17 June 2004 (Category:Oncology). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 16:30, 17 June 2004 by Hcheney (talk | contribs) (Category:Oncology)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)]
Subcategories
This category has the following 13 subcategories, out of 13 total.
A
- Alternative cancer treatments (1 C, 81 P)
- Antineoplastic drugs (17 C, 215 P)
C
- Cancer hormone therapy (1 P)
- Cereblon E3 ligase modulators (7 P)
- Chemotherapy (4 C, 36 P)
- Combination cancer drugs (12 P)
E
- Experimental cancer treatments (2 C, 34 P)
I
- Cancer immunotherapy (1 C, 19 P)
O
- Oncothermia (6 P)
R
- Radiation therapy (3 C, 68 P)
S
- Surgical oncology (65 P)
T
- Targeted therapy (7 P)
V
- Cancer vaccines (28 P)
Pages in category "Cancer treatments"
The following 113 pages are in this category, out of 113 total. This list may not reflect recent changes.
*
A
- Abscopal effect
- Active surveillance of low-risk papillary thyroid microcarcinoma
- Active surveillance of prostate cancer
- Adjuvant therapy
- ALECSAT
- Alternating electric field therapy
- Anti-malignin antibody
- Anti-VEGF
- Autogene cevumeran
- Autologous immune enhancement therapy
- Autologous patient-specific tumor antigen response
- Axicabtagene ciloleucel
B
C
- Cancer Drugs Fund
- Cancer pharmacogenomics
- Cancer rehabilitation
- Carmustine
- Chemosensitivity assay
- Chemotherapy
- Cisplatin
- Cobimetinib
- CXCR4 antagonist
- Cytarabine
- Cytokine-induced killer cell
D
E
F
- Fedratinib
- FLASH Radiotherapy
- Focused ultrasound for intracranial drug delivery
- Fruquintinib
- Functional Assessment of Cancer Therapy - General
G
H
- High-dose chemotherapy and bone marrow transplant
- HER2
- William Henry Hosking
- Host response to cancer therapy
I
L
- Lasers in cancer treatment
- Lifileucel
- Linear particle accelerator
- Lisocabtagene maraleucel
- Lomustine
- Lymphatogenous metastasis
M
N
- Nadofaragene firadenovec
- Neoadjuvant therapy
- NeuVax
- NGR-hTNF (antitumor recombinant protein)
- Nigro protocol
- Niraparib/abiraterone acetate
- Nitrogen mustard
- NK-92
O
P
- Panobinostat
- Peptide receptor radionuclide therapy
- Percutaneous hepatic perfusion
- PH-responsive tumor-targeted drug delivery
- PHEC-66
- Photodynamic therapy
- Photostatin
- Plasmonic nanoparticles
- Predictive marker
- Prehabilitation
- Procarbazine
- Prophylactic cranial irradiation
- Management of prostate cancer
R
S
T
- Tabelecleucel
- Tagraxofusp
- Targeted alpha-particle therapy
- Targeted therapy of lung cancer
- Tazemetostat
- Temozolomide
- Thiotepa
- Tislelizumab
- Tivozanib
- Trametinib
- Treatment of lung cancer
- Tucatinib
- Tumor board review
- Tumour heterogeneity